ATE211743T1 - Substituierte 3-aminochinuclidine - Google Patents

Substituierte 3-aminochinuclidine

Info

Publication number
ATE211743T1
ATE211743T1 AT92911350T AT92911350T ATE211743T1 AT E211743 T1 ATE211743 T1 AT E211743T1 AT 92911350 T AT92911350 T AT 92911350T AT 92911350 T AT92911350 T AT 92911350T AT E211743 T1 ATE211743 T1 AT E211743T1
Authority
AT
Austria
Prior art keywords
compounds
aminochinuclidines
substituted
disorders
antagonists
Prior art date
Application number
AT92911350T
Other languages
English (en)
Inventor
Fumitaka Ito
Toshihide Kokura
Masami Nakane
Kunio Satake
Hiroaki Wakabayashi
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE211743T1 publication Critical patent/ATE211743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
AT92911350T 1991-05-22 1992-05-19 Substituierte 3-aminochinuclidine ATE211743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14682691 1991-05-22
PCT/US1992/004002 WO1992020676A1 (en) 1991-05-22 1992-05-19 Substituted 3-aminoquinuclidines

Publications (1)

Publication Number Publication Date
ATE211743T1 true ATE211743T1 (de) 2002-01-15

Family

ID=15416402

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92911350T ATE211743T1 (de) 1991-05-22 1992-05-19 Substituierte 3-aminochinuclidine

Country Status (25)

Country Link
EP (1) EP0585328B1 (de)
KR (1) KR100246065B1 (de)
CN (1) CN1041827C (de)
AT (1) ATE211743T1 (de)
AU (1) AU658898B2 (de)
BR (1) BR9206044A (de)
CA (1) CA2109415C (de)
CZ (1) CZ247993A3 (de)
DE (2) DE9290057U1 (de)
DK (1) DK0585328T3 (de)
EG (1) EG20218A (de)
ES (1) ES2168260T3 (de)
FI (1) FI935134L (de)
HU (1) HUT65771A (de)
IE (1) IE921662A1 (de)
IL (1) IL101960A (de)
MX (1) MX9202449A (de)
NO (1) NO305173B1 (de)
NZ (2) NZ242880A (de)
PL (4) PL171921B1 (de)
PT (1) PT100514B (de)
RU (1) RU2092486C1 (de)
UA (1) UA26401C2 (de)
WO (1) WO1992020676A1 (de)
ZA (1) ZA923773B (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5138060A (en) * 1991-01-03 1992-08-11 Pfizer Inc. Process and intermediates for preparing azabicyclo(2.2.2)octan-3-imines
FI990419A7 (fi) * 1991-06-20 1999-02-26 Pfizer Typpeä sisältävien hetrosyklisten yhdisteiden fluorialkoksibentsyyliaminojohdannaiset
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
ATE208376T1 (de) * 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
JP2656699B2 (ja) * 1992-10-21 1997-09-24 ファイザー製薬株式会社 置換ベンジルアミノキヌクリジン
US5837711A (en) * 1992-10-28 1998-11-17 Pfizer Inc. Substituted quinuclidines as substance P antagonists
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
CA2150123C (en) * 1992-12-10 2004-12-07 Harry R. Howard Aminomethylene substituted non-aromatic heterocycles
IL109646A0 (en) * 1993-05-19 1994-08-26 Pfizer Heteroatom substituted alkyl benzylamino-quinuclidines
JP2822274B2 (ja) * 1993-05-19 1998-11-11 ファイザー製薬株式会社 Ｐ物質拮抗剤としてのヘテロ原子置換アルキルベンジルアミノキヌクリジン類
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
WO1995002595A1 (en) * 1993-07-15 1995-01-26 Pfizer Inc. Benzyloxyquinuclidines as substance p antagonists
US6083943A (en) * 1993-09-17 2000-07-04 Pfizer Inc Substituted azaheterocyclecarboxylic acid
WO1995007886A1 (en) * 1993-09-17 1995-03-23 Pfizer Inc. 3-amino-5-carboxy-substituted piperidines and 3-amino-4-carboxy-substituted pyrrolidines as tachykinin antagonists
EP0653208A3 (de) * 1993-11-17 1995-10-11 Pfizer Substanz P Antagonisten zur Behandlung oder Verhütung des sonnenbrandes.
EP0659409A3 (de) * 1993-11-23 1995-08-09 Pfizer Substanz P Antagonisten zur Hemmung der Angiogenese.
EP0655246A1 (de) * 1993-11-30 1995-05-31 Pfizer Inc. Substanz P Antagonisten zur Behandlung von durch Helicobacter Pylori oder andere spirale Urease-positive Gram-negative Bakterien verursachten Krankheiten
FR2728169A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des prurits et des dysesthesies oculaires ou palpebrales
FR2728166A1 (fr) 1994-12-19 1996-06-21 Oreal Composition topique contenant un antagoniste de substance p
FR2728165A1 (fr) 1994-12-19 1996-06-21 Oreal Utilisation d'un antagoniste de substance p pour le traitement des rougeurs cutanees d'origine neurogene
PE8798A1 (es) * 1995-07-17 1998-03-02 Pfizer Procedimiento de separacion de los enantiomeros del 1-azabiciclo[2.2.2] octan-3-amina, 2-(difenilmetil) -n- [[2-metoxi-5-(1-metiletil) fenil] metil]
TW458774B (en) 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
NZ329807A (en) * 1997-04-23 2000-07-28 Pfizer NK-1 receptor antagonists and P receptor antagonists 2-Diarylmethyl-3-amino-1-azabicyclo[2.2.2]octane derivatives and amino substituted N-containing rings as agents for treating irritable bowel syndrome
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
MXPA02004330A (es) 1999-11-03 2004-07-30 Albany Molecular Res Inc Tetrahidroisoquinolinas aril-y heteroaril-sustituidas y uso de las mismas para bloquear la recaptacion de norepinefrina, dopamina y serotonina..
KR100821410B1 (ko) 2000-07-11 2008-04-10 에이엠알 테크놀로지, 인크. 4-페닐 치환된 테트라하이드로이소퀴놀린 및 이의치료학적 용도
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6861526B2 (en) * 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
RU2240689C1 (ru) * 2003-08-07 2004-11-27 Государственное научное учреждение Научно-исследовательский ветеринарный институт Нечерноземной зоны Российской Федерации Препарат для пастбищной профилактики фасциолеза сельскохозяйственных животных, способ его получения и применения
NZ552397A (en) 2004-07-15 2011-04-29 Amr Technology Inc Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
EP1940842B1 (de) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
JP4611444B2 (ja) 2007-01-10 2011-01-12 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール
EP2117538A1 (de) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmazeutische zusammensetzungen mit 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
AU2009222122A1 (en) 2008-03-03 2009-09-11 Tiger Pharmatech Tyrosine kinase inhibitors
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
AU2010247735B2 (en) 2009-05-12 2015-07-16 Albany Molecular Research, Inc. Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)- 1,2,3,4-tetrahydroisoquinoline and use thereof
AU2010247763B2 (en) 2009-05-12 2015-12-24 Albany Molecular Research, Inc. 7-([1,2,4,]triazolo[1,5,-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4- tetrahydroisoquinoline and use thereof
PE20121172A1 (es) 2009-10-14 2012-09-05 Merck Sharp & Dohme Piperidinas sustituidas con actividad en la hdm2
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP3330377A1 (de) 2010-08-02 2018-06-06 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte hemmung der catenin (cadherin-assoziiertes protein)-beta-1 (ctnnb1)- genexpression mittels kurzer interferierender nukleinsäuren (sina)
US9029341B2 (en) 2010-08-17 2015-05-12 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
AU2012245971A1 (en) 2011-04-21 2013-10-17 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
US20150299696A1 (en) 2012-05-02 2015-10-22 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3525785B1 (de) 2016-10-12 2025-08-27 Merck Sharp & Dohme LLC Kdm5-inhibitoren
EP3706747B1 (de) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
US12173026B2 (en) 2018-08-07 2024-12-24 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP3833668B1 (de) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5-inhibitoren
US11981701B2 (en) 2018-08-07 2024-05-14 Merck Sharp & Dohme Llc PRMT5 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas

Also Published As

Publication number Publication date
KR100246065B1 (en) 2000-04-01
EG20218A (en) 1997-11-30
EP0585328A1 (de) 1994-03-09
PL170513B1 (en) 1996-12-31
ES2168260T3 (es) 2002-06-16
PL171921B1 (pl) 1997-06-30
PT100514A (pt) 1993-09-30
CA2109415C (en) 1998-12-29
HUT65771A (en) 1994-07-28
AU658898B2 (en) 1995-05-04
NZ272941A (en) 1997-05-26
NZ242880A (en) 1995-10-26
CA2109415A1 (en) 1992-11-23
PL170525B1 (en) 1996-12-31
DE69232334D1 (de) 2002-02-14
CZ247993A3 (en) 1994-07-13
NO305173B1 (no) 1999-04-12
CN1041827C (zh) 1999-01-27
IE921662A1 (en) 1992-12-02
DK0585328T3 (da) 2002-02-11
HU9303307D0 (en) 1994-03-28
AU1927592A (en) 1992-12-30
FI935134A0 (fi) 1993-11-19
NO934195L (no) 1993-11-19
BR9206044A (pt) 1995-03-01
DE69232334T2 (de) 2002-11-14
NO934195D0 (no) 1993-11-19
RU2092486C1 (ru) 1997-10-10
WO1992020676A1 (en) 1992-11-26
DE9290057U1 (de) 1994-01-05
IL101960A0 (en) 1994-04-12
PT100514B (pt) 1999-06-30
MX9202449A (es) 1993-03-01
FI935134A7 (fi) 1993-11-19
FI935134L (fi) 1993-11-19
ZA923773B (en) 1993-11-22
CN1068571A (zh) 1993-02-03
EP0585328B1 (de) 2002-01-09
PL172069B1 (pl) 1997-07-31
IL101960A (en) 1999-03-12
UA26401C2 (uk) 1999-08-30

Similar Documents

Publication Publication Date Title
ATE211743T1 (de) Substituierte 3-aminochinuclidine
MY107157A (en) Quinuclidine derivatives.
MY130145A (en) Quinuclidine derivative for treatment of inflammatory and gastrointestinal disorders.
RU93058351A (ru) Замещенные 3-аминохинуклидины, фармацевтические композиции на его основе, способы лечения, способ получения, промежуточные соединения
RU93058555A (ru) Производные хинуклидина, способ их получения, фармацевтическая композиция, способ лечения или профилактики
LU91223I2 (fr) Ivabradine et ses dérivés pharmaceutiquement acceptables (procoralan)
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE69530988D1 (de) Benzimidazolderivate mit dopaminerger wirkung
KR950700286A (ko) 2,3,4,5-테트라하이드로-1H-3-벤즈아제핀 및 약제학적으로 허용가능한 이의 산 부가염(2,3,4,5-Tetrahydro-1H-3-benzazepines and pharmaceutically acceptable acid addition salts thereof)
MX10256A (es) Procedimiento para preparar nuevas 3-fenil-7h-tiazolo(3, 2-b) (1, 2, 4) triazin-7-onas.
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
TH32887A (th) สารประกอบทางเคมี

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee